GMR
The Original

CRISPR-CAS GENOME EDITING AND MOLECULAR DIAGNOSTICS: EMERGING PERSPECTIVES IN GENETICS AND BIOCHEMICAL RESEARCH

Dr. Pavithra M[1*], Dr. R. Sathya[2], Gautham Suresh S P[3], Bhavna Rajkumari[4], Monika S [5], Faraha Naaz Rasool[6], Upasna Mishra[7], Sakthivel Senthilkumar[8]

[1]Ph.D Scholar; Tamil Nadu Agricultural University, Coimbatore; Email: paviuvassri@gmail.com
[2]Assistant Professor (Senior grade); SRM COLLEGE Of AGRICULTURAL SCIENCES
[3]Ph.D. Scholar; University of Horticultural Sciences, Bagalkot
[4]Young Professional, Aicrp On Seed (Crops); Central Agricultural University, Imphal, Manipur-795004
[5]PhD scholar; Anbil Dharmalingam Agricultural College and Research Institute, Tamil Nadu Agricultural University, Tiruchirappalli
[6]Deputy Director Training, Directorate of extension; SKUAST, Kashmir, Shalimar, Srinagar- 190001
[7]M.Sc (Ag) Plant Breeding & Genetics (completed); Rajmata Vijayaraje Scindhia Krishi Vishwa Vidyalaya (RVSKVV), Gwalior (M.P.)
[8]Guest Faculty, Department of Plant Pathology; CSA University of Agriculture and Technology, Kanpur.

ABSTRACT

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their associated (Cas) proteins have progressed from an obscure, unannotated repeat sequence first noted in Escherichia coli in 1987 to one of the most versatile toolkits in modern genetics and biochemistry. This chapter provides an expanded, detailed synthesis of CRISPR-Cas biology: its historical discovery and immunological origins — including the experimental confirmation of CRISPR as an adaptive immune system and the discovery of tracrRNA — the classification and structural biochemistry of Class 1 and Class 2 CRISPR-Cas systems (including the Cas9, Cas12, and Cas13 effector families and the crystal structure of the Cas9-sgRNA-DNA complex), the phage-derived anti-CRISPR proteins that naturally inhibit Cas activity, programmable transcriptional and epigenetic regulation (CRISPRi/CRISPRa), and the rapidly diversifying family of editing modalities encompassing nucleases, base editors, and prime editors, along with the distinct guide-RNA-independent off-target mechanism recently identified for cytosine base editors. It further examines how the same collateral-cleavage biochemistry that underlies genome editing has been independently repurposed for ultrasensitive molecular diagnostics, with particular attention to the SHERLOCK, DETECTR, and electronic CRISPR-Chip platforms and their clinical validation during the COVID-19 pandemic. Applications in functional genomics screening, agricultural biotechnology, and both ex vivo and in vivo therapeutics are reviewed alongside delivery strategies, empirical off-target detection methods, and the regulatory and ethical frameworks shaping clinical translation, including the 2018 heritable-editing controversy. Six original diagrams — spanning a historical timeline, CRISPR-Cas system classification, the Cas9 cleavage mechanism, the evolution of editing modalities, collateral-cleavage biochemistry, and the CRISPR diagnostic workflow — are provided to support conceptual understanding, alongside two comparative tables. The chapter closes with a discussion of open challenges and future research directions connecting basic CRISPR biology to applied genetic and biochemical research.

KEYWORDS: CRISPR-Cas9, genome editing, base editing, prime editing, molecular diagnostics, SHERLOCK, DETECTR, CRISPR-Chip, off-target effects, functional genomics, CRISPRi/CRISPRa, biochemical research

1. INTRODUCTION

Genome editing technologies have redefined the pace at which genetic hypotheses can be tested and translated into therapeutic and diagnostic applications. Among these, the CRISPR-Cas system stands out for its programmability, low cost, modularity, and adaptability across virtually all domains of life. Originally characterised as a prokaryotic adaptive immune mechanism that stores fragments of invading viral or plasmid DNA as spacers within CRISPR arrays, the system was repurposed for site-specific genome engineering following the demonstration that a single engineered guide RNA could direct the Cas9 nuclease to introduce a double-strand break at a chosen genomic locus (Jinek et al., 2012).

This discovery, and near-simultaneous reports of CRISPR-Cas9 activity in mammalian and human cells (Cong et al., 2013; Mali et al., 2013), catalysed just over a decade of rapid methodological diversification: from blunt double-strand-break editing to precision base and prime editing, from single-gene perturbation to genome-scale functional screens, and, notably, to nucleic-acid diagnostics that exploit the collateral, non-specific nuclease activity of certain Cas effectors. The scientific significance of this body of work was formally recognised when Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for the development of a method for genome editing.

This chapter offers an expanded review of these developments, with emphasis on the mechanistic biochemistry underlying each platform, worked comparisons between editing modalities and diagnostic platforms, supporting diagrams, and a discussion of the practical and ethical considerations shaping the field's translational trajectory.

1.1 Scope and Organisation

Section 1.2 traces the historical discovery of CRISPR from its first observation in 1987 to its clinical translation. Section 2 introduces the natural biology and classification of CRISPR-Cas systems, the structural basis of Cas9 target recognition, and CRISPR-based transcriptional and epigenetic regulation. Section 3 details the progression from nuclease-based editing to base and prime editing. Section 4 surveys translational and functional-genomics applications, including both ex vivo and in vivo therapeutics. Section 5 addresses delivery strategies and empirical off-target specificity. Section 6 examines CRISPR-based molecular diagnostics in depth, including their biochemical design, electronic readout platforms, and pandemic-era clinical validation. Section 7 discusses the convergence of editing and diagnostic biochemistry, Section 8 reviews agricultural and environmental applications, Section 9 discusses ethical and regulatory dimensions including heritable-editing governance, and Section 10 concludes with future directions.

1.2 Historical Background

The path from an obscure bacterial genomic curiosity to a Nobel Prize-winning biotechnology spanned exactly twenty-five years. Repetitive genomic sequences later recognised as CRISPR were first reported, without functional explanation, in the 3' flanking region of the Escherichia coli iap gene, where five near-identical 29-nucleotide repeats were found separated by 32-nucleotide spacers (Ishino et al., 1987). For nearly a decade and a half these repeats attracted little attention; it was not until comparative genomic surveys identified similar interspersed repeat structures across diverse archaea and bacteria that the field acquired a name, when Jansen and colleagues coined the acronym CRISPR and identified the neighbouring CRISPR-associated (cas) genes (Jansen et al., 2002).

The functional significance of the variable spacer sequences remained unclear until bioinformatic analyses revealed that many spacers were identical to fragments of bacteriophage and plasmid genomes, leading independent groups to propose that CRISPR loci constitute a heritable, sequence-specific prokaryotic immune record of prior viral or plasmid encounters (Mojica et al., 2005). This immunological hypothesis was subsequently confirmed experimentally, setting the stage for the biochemical dissection of the interference mechanism and, ultimately, the 2012 demonstration of a programmable single-guide RNA capable of directing Cas9 to cleave any chosen DNA sequence (Jinek et al., 2012). Figure 1 places these milestones on a single historical timeline, extending through the discovery of the Cas12a (Cpf1) effector family and the emergence of CRISPR diagnostics to the first regulatory approval of a CRISPR-edited cell therapy.

Figure 1. Historical Timeline: From Discovery to Clinical Translation



Figure 1. Historical timeline from the initial 1987 observation of repetitive bacterial DNA sequences through the establishment of programmable Cas9 editing, the discovery of the Cas12a effector family, the launch of CRISPR-based diagnostics, the 2020 Nobel Prize in Chemistry, and the first regulatory-approved and in-vivo clinical applications.

2. Molecular Architecture and Mechanism of CRISPR-Cas Systems

2.1 Natural CRISPR-Cas Immunity

CRISPR loci consist of short repeated sequences interspersed with variable spacer sequences derived from previously encountered mobile genetic elements such as bacteriophages and plasmids. The adaptive immune cycle proceeds in three broad stages. During adaptation, fragments of foreign DNA are captured and integrated into the CRISPR array as new spacers. During expression, the locus is transcribed into a long precursor CRISPR RNA (pre-crRNA) that is processed into mature, individual crRNAs. During interference, mature crRNAs guide Cas effector proteins to complementary invading nucleic acid, resulting in its recognition and degradation. The first direct experimental evidence that CRISPR loci function as an adaptive, heritable immune system came from work in Streptococcus thermophilus, where challenge with bacteriophage was shown to drive integration of new, phage-derived spacers, and where the deliberate removal or addition of specific spacers correspondingly altered the resulting phage-resistance phenotype in a cas-gene-dependent manner (Barrangou et al., 2007).

A second key mechanistic discovery clarified how the precursor CRISPR transcript is processed into individual, functional crRNAs. In Streptococcus pyogenes, this processing was found to depend on a small trans-encoded RNA, subsequently named trans-activating crRNA (tracrRNA), acting together with the housekeeping endoribonuclease RNase III (Deltcheva et al., 2011). This discovery of tracrRNA proved pivotal: it directly enabled the recognition, a year later, that a single synthetic RNA fusing crRNA and tracrRNA could substitute for the natural dual-RNA guide, providing the essential biochemical simplification underlying the sgRNA design used in programmable Cas9 editing (Section 2.3).

2.2 Classification of CRISPR-Cas Systems

CRISPR-Cas systems are broadly divided into two classes based on the architecture of their interference machinery. Class 1 systems (Types I, III, and IV) employ multi-subunit effector complexes composed of several distinct Cas proteins that act together to recognise and degrade target nucleic acid. Class 2 systems (Types II, V, and VI) instead rely on a single, large multidomain effector protein guided by RNA — Cas9 in Type II systems, Cas12 variants in Type V systems, and the RNA-targeting Cas13 in Type VI systems. This structural simplicity is precisely what makes Class 2 systems tractable for biotechnological repurposing: a single protein, combined with a synthetic guide RNA, is sufficient to reconstitute programmable, sequence-specific nucleic acid recognition outside of its native bacterial context.

Figure 2. Classification of CRISPR-Cas Systems



Figure 2. Classification of CRISPR-Cas systems into Class 1 (multi-subunit effector complexes; Types I, III, IV) and Class 2 (single-protein effectors; Types II, V, VI). Class 2 effectors — Cas9, Cas12, and Cas13 — provide the simplest chassis for biotechnological repurposing and underlie the editing and diagnostic platforms discussed in this chapter.

2.2.1 The Cas12 and Cas13 Effector Families

Beyond Cas9, a structurally distinct Class 2 effector family was identified through targeted genome mining for putative nuclease-associated loci lacking recognisable Cas9 homology. This effort characterised Cpf1 (subsequently renamed Cas12a) as a single RNA-guided endonuclease of a novel Type V CRISPR-Cas system (Zetsche et al., 2015). Unlike Cas9, Cas12a requires only a single crRNA (no separate tracrRNA), recognises a T-rich PAM positioned upstream of the protospacer, and generates a staggered rather than blunt double-strand break — properties that have made it attractive both for multiplexed genome editing, since a single Cas12a transcript can process its own crRNA array, and, as discussed in Section 6, for nucleic acid diagnostics via its collateral single-stranded DNase activity. Genome-wide profiling subsequently showed that Cas12a orthologues exhibit substantially lower off-target activity than wild-type Cas9 under comparable conditions (Kleinstiver et al., 2016), reinforcing interest in Cas12a as a complementary, and in some respects more specific, editing platform. The Type VI effector Cas13, by contrast, targets single-stranded RNA rather than DNA via twin HEPN ribonuclease domains and underlies both the SHERLOCK diagnostic platform (Section 6.2) and emerging RNA-editing and RNA-knockdown applications that avoid permanent modification of the genome.

2.2.2 CRISPR-Based Transcriptional and Epigenetic Regulation

A catalytically inactivated ('dead') Cas9 (dCas9), lacking both HNH and RuvC nuclease activity but retaining RNA-guided DNA-binding capacity, provided the basis for repurposing CRISPR as a programmable gene-regulation platform rather than a DNA-cutting tool. Fusion of dCas9 to a bacterial or eukaryotic repressor domain enabled CRISPR interference (CRISPRi), in which guide-RNA-directed binding alone sterically blocks transcriptional elongation or RNA polymerase recruitment to achieve robust, reversible gene silencing without introducing any DNA break (Qi et al., 2013). The complementary approach, CRISPR activation (CRISPRa), fuses dCas9 to transcriptional activator domains to achieve programmable upregulation of endogenous genes (Gilbert et al., 2013). Because these tools modulate gene expression without altering the underlying DNA sequence, they are widely used for genome-scale gain- and loss-of-function screening (see Section 4.2) and for functional dissection of non-coding regulatory elements, and represent a further axis of CRISPR-derived biochemical versatility distinct from both the sequence-editing tools of Section 3 and the diagnostic applications of Section 6.

2.3 The Cas9 Dual-RNA Mechanism

The pivotal biochemical insight enabling programmable genome editing was that Cas9 requires both a crRNA and a trans-activating crRNA (tracrRNA), and that these two RNA molecules can be fused into a single synthetic guide RNA (sgRNA) capable of directing site-specific double-stranded DNA cleavage (Jinek et al., 2012). Target recognition additionally requires a short protospacer-adjacent motif (PAM) immediately downstream of the target sequence on the non-target strand; PAM recognition licenses local DNA unwinding and formation of an RNA-DNA heteroduplex (the 'R-loop') between the guide and the complementary genomic strand.

Once the R-loop is fully formed, the HNH and RuvC-like nuclease domains of Cas9 cleave the complementary and non-complementary DNA strands, respectively, generating a blunt double-strand break positioned approximately three base pairs upstream of the PAM. Figure 3 summarises this mechanism schematically.

Figure 3. CRISPR-Cas9 Dual-RNA-Guided DNA Cleavage



Figure 3. CRISPR-Cas9 dual-RNA-guided DNA cleavage. The sgRNA (fusing crRNA and tracrRNA) directs Cas9 to a genomic target adjacent to a PAM sequence. The HNH domain cleaves the strand complementary to the guide RNA, while the RuvC-like domain cleaves the non-complementary strand, generating a blunt double-strand break that is subsequently repaired by NHEJ or HDR. (Adapted conceptually from Jinek et al., 2012.)

The resulting break is repaired by the cell's endogenous DNA repair machinery via one of two principal pathways. Non-homologous end joining (NHEJ) is the dominant, error-prone pathway in most cell types and typically introduces small insertions or deletions (indels) at the cleavage site, making it well suited for gene disruption. Homology-directed repair (HDR) instead uses a homologous donor template — either an endogenous sister chromatid or an exogenously supplied construct — to achieve precise sequence replacement, but proceeds at markedly lower efficiency because it is largely restricted to the S and G2 phases of the cell cycle. Independent confirmation that this dual-RNA-guided mechanism could be engineered for multiplexed genome editing directly in human and mouse cells followed within the same year (Cong et al., 2013; Mali et al., 2013), establishing CRISPR-Cas9 as a general-purpose eukaryotic genome-engineering tool.

2.4 Structural Basis of Target Recognition and Fidelity

Subsequent crystallographic and single-molecule biophysical studies clarified how Cas9 undergoes a stepwise conformational activation upon sgRNA loading, and how the HNH domain must physically reposition relative to the RuvC domain before catalysis can proceed. A landmark crystal structure of Streptococcus pyogenes Cas9 in complex with a chimeric single-guide RNA and its target DNA directly visualised this bilobed architecture, showing how the guide RNA and target DNA heteroduplex are threaded through a positively charged channel between the enzyme's recognition and nuclease lobes (Nishimasu et al., 2014). This conformational checkpoint provides a structural rationale for the enzyme's PAM-dependent fidelity, while also explaining its propensity for off-target cleavage at genomic sites bearing partial complementarity to the guide sequence — particularly when mismatches occur distal to the PAM. This structural understanding directly informed the subsequent engineering of high-fidelity Cas9 variants with reduced off-target activity, discussed further in Section 5.

2.5 Anti-CRISPR Proteins: Natural Off-Switches

The evolutionary arms race between bacteriophages and their CRISPR-equipped bacterial hosts has produced a further biochemical resource of direct relevance to genome-editing control: anti-CRISPR (Acr) proteins. First identified in phages capable of infecting and killing Pseudomonas aeruginosa strains bearing an otherwise fully functional Type I-F CRISPR-Cas system, these small phage-encoded proteins directly inhibit CRISPR-Cas interference by a variety of mechanisms, including blocking guide RNA loading, occluding the PAM-recognition

surface, or sterically preventing DNA binding altogether (Bondy-Denomy et al., 2013). Related Acr families have since been characterised against Type II Cas9 and Type V Cas12a systems. Because Acr proteins can be co-delivered or co-expressed with Cas effectors to provide a temporally and spatially controllable 'off-switch,' they have found direct application as tunable genome-editing control elements, offering a route to reduce the cumulative window of nuclease activity and, correspondingly, the risk of off-target editing discussed in Section 5.2.

3. From Double-Strand Breaks to Precision Editing

3.1 Nuclease-Based Editing and Its Limitations

Classical Cas9- or Cas12a-mediated editing relies on the deliberate introduction of a double-strand break, an outcome that is biochemically effective for gene disruption but carries several limitations for precision applications. Break repair by NHEJ is stochastic, producing a heterogeneous mixture of indel outcomes at a given locus rather than a single defined edit. Double-strand breaks can also trigger a p53-dependent DNA damage response that may select against successfully edited cells, and, particularly at high multiplicity of guide RNA delivery, can lead to larger structural rearrangements, translocations, or loss of chromosomal segments. These limitations motivated the development of 'base-first' editing strategies that avoid double-strand breaks altogether while retaining the programmability of RNA-guided targeting.

3.2 Base Editing

Base editors couple a catalytically impaired Cas9 — either a nickase (nCas9) that cleaves only one DNA strand, or a fully catalytically dead Cas9 (dCas9) — to a nucleotide deaminase domain, enabling direct, irreversible conversion of one base pair to another without generating a double-strand break. Cytosine base editors (CBEs) use a cytidine deaminase to convert C•G to T•A base pairs (Komor et al., 2016), while adenine base editors (ABEs), engineered via directed evolution of a bacterial deoxyadenosine deaminase to accept single-stranded DNA substrates, convert A•T to G•C base pairs (Gaudelli et al., 2017). Together, these two editor classes address the majority of known human pathogenic point mutations, which are disproportionately transition mutations.

Mechanistically, the nCas9 component nicks the non-edited strand once the deaminase has acted on the exposed single-stranded DNA within the R-loop, biasing the cell's mismatch repair machinery to use the edited strand as the template for resolving the mismatch, thereby increasing editing efficiency and product purity. These tools substantially reduce indel by-products relative to nuclease editing, although they remain constrained to transition mutations (not transversions) and to a defined editing window within the R-loop determined by the deaminase's accessible range.

Base editors are not immune to off-target activity, and the nature of this off-target risk differs qualitatively from the guide-RNA-dependent, sequence-similarity-driven off-target cleavage associated with nuclease editing (Section 5.2). Using a two-cell mouse embryo injection strategy that allowed direct comparison between an edited and an isogenic unedited blastomere within the same embryo, cytosine base editors were shown to induce substantial numbers of genome-wide single-nucleotide variants at sites bearing no relationship to the guide RNA sequence, implying a guide-RNA-independent, deaminase-driven mutagenic mechanism; adenine base editors and conventional Cas9 nuclease editing did not show this effect under the same conditions (Zuo et al., 2019). An independent whole-genome sequencing study of edited rice plants reported a parallel finding, again showing that cytosine, but not adenine, base editors generate substantial genome-wide off-target mutations undetectable by conventional computational off-target prediction tools. Together, these studies established that base-editor specificity must be evaluated by mechanisms distinct from those used for nuclease off-target profiling, and have motivated engineering efforts toward deaminase variants with reduced spurious, guide-RNA-independent activity.

3.3 Prime Editing

Prime editing extends the precision-editing paradigm further by fusing a Cas9 H840A nickase to an engineered reverse transcriptase and pairing it with a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit directly within an extension of the guide RNA itself. This 'search-and-replace' mechanism operates by nicking the target strand, using the nicked 3' end as a primer for reverse transcription off the pegRNA template, and thereby writing new genetic information directly into the genome. In principle, prime editing can install all twelve possible base-to-base conversions as well as small insertions and deletions, without requiring a double-strand break or a separate exogenous donor DNA template (Anzalone et al., 2019).

Because prime editing writes new sequence information directly from an RNA template rather than relying on the comparatively inefficient and genotoxic HDR pathway, it substantially broadens the mutational landscape addressable by direct genome writing, and has been described as offering a fourth, complementary axis of CRISPR-derived editing agents alongside nucleases, base editors, and site-specific recombinases/transposases (Anzalone et al., 2020).

3.4 Comparative Summary

Table 1 summarises the principal biochemical and functional distinctions among nuclease editing, base editing, and prime editing, alongside the diagnostic use of Cas effectors discussed in Section 6.

Table 1. Comparison of CRISPR-Cas editing modalities and diagnostic applications.

Feature	Nuclease Editing	Base Editing	Prime Editing	CRISPR Diagnostics
Effector	Cas9 / Cas12a	nCas9-deaminase fusion	nCas9-reverse transcriptase fusion	Cas13a, Cas12a, Cas12b
DNA break?	Double-strand break	None (nick only)	None (nick only)	Not applicable (detection)
Edit type	Indels, knockouts, HDR insertions	Single transition mutations	All 12 conversions, small indels	Sequence identification only
Precision	Moderate; stochastic repair	High within editing window	Very high; template-defined	Single-nucleotide discrimination
Representative reference	Jinek et al., 2012	Komor et al., 2016	Anzalone et al., 2019	Gootenberg et al., 2017

Figure 4. Evolution of CRISPR-Cas Genome Editing Modalities



Figure 4. Evolution of CRISPR-Cas genome editing modalities, from nuclease-based double-strand-break editing (2012-13) through base editing (2016-17) to prime editing (2019), alongside the parallel emergence of CRISPR-based diagnostics exploiting collateral-cleavage biochemistry.

4. Translational and Functional Genomics Applications

4.1 Therapeutic Genome Editing

The maturation of CRISPR-based editing has translated into approved clinical practice. In December 2023, the United States Food and Drug Administration approved exagamglogene autotemcel (exa-cel; marketed as Casgevy), an ex vivo CRISPR-Cas9-edited autologous haematopoietic stem cell therapy for sickle cell disease and, subsequently, transfusion-dependent β-thalassaemia. This approval marked the first FDA-approved therapy built on CRISPR-Cas9 gene editing, and works by disrupting a regulatory element controlling BCL11A expression to reactivate fetal haemoglobin production, compensating for defective adult haemoglobin; efficacy and safety in the pivotal cohort were reported in a multicentre clinical trial (Frangoul et al., 2021).

A parallel and mechanistically distinct milestone was achieved with NTLA-2001, the first therapeutic to demonstrate direct in vivo CRISPR-Cas9 genome editing in humans. Rather than editing cells ex vivo, NTLA-2001 uses lipid nanoparticles to deliver Cas9 mRNA and a guide RNA targeting the transthyretin (TTR) gene directly to hepatocytes, achieving dose-dependent, durable reduction of serum TTR protein in patients with hereditary transthyretin amyloidosis after a single intravenous infusion (Gillmore et al., 2021). Together, exa-cel and NTLA-2001 illustrate the two principal therapeutic delivery paradigms available to CRISPR medicine — ex vivo cell editing followed by reinfusion, and direct in vivo editing of a target organ — each carrying distinct trade-offs in manufacturing complexity, delivery efficiency, and durability of effect, discussed further in Section 5.1. This clinical progress, alongside a growing pipeline of base- and prime-editing therapeutics in trials for haemoglobinopathies and other monogenic disorders, illustrates the shift of CRISPR technology from a discovery-science tool to an approved biochemical intervention, while also foregrounding practical challenges of delivery, manufacturing cost, and equitable global access.

4.2 Functional Genomics Screening

Beyond therapeutic editing, the programmability of Cas9 has enabled genome-scale functional genomics at a scale previously unattainable with RNA-interference-based methods. Pooled lentiviral libraries encoding tens of thousands of distinct guide RNAs allow parallel, genome-wide loss-of-function screening in a single experiment: cells receiving guides against genes required for a given phenotype (for example, survival under drug selection)

are depleted from the population over time, and guide-RNA abundance sequencing after selection identifies the responsible genes (Shalem et al., 2014). Because CRISPR-mediated gene disruption is more complete than partial knockdown by RNA interference, these screens typically yield higher signal-to-noise ratios and have become a standard tool for identifying cancer-cell vulnerabilities, drug-resistance mechanisms, and gene networks underlying diverse cellular phenotypes.

Related technologies extend this logic to gene regulation rather than disruption: CRISPR interference (CRISPRi) uses a catalytically dead Cas9 fused to a transcriptional repressor domain to reversibly silence gene expression, while CRISPR activation (CRISPRa) fuses dCas9 to transcriptional activator domains to upregulate target genes, together enabling genome-wide gain- and loss-of-function screening without permanently altering the underlying DNA sequence.

4.3 Agricultural and Environmental Biotechnology

CRISPR-based editing has also been widely adopted in crop and livestock improvement, where it is used to introduce disease resistance, improve stress tolerance, modify nutritional composition, and accelerate domestication of orphan crops without necessarily introducing foreign transgenic DNA — a distinction that has shaped a more permissive regulatory posture toward CRISPR-edited crops in several jurisdictions relative to earlier transgenic technologies. Because such applications intersect directly with soil, crop, and remote-sensing-based agricultural research, CRISPR-derived molecular markers and rapid genotyping diagnostics are of growing relevance to precision agriculture and integrated crop-monitoring programmes.

5. Delivery Strategies and Off-Target Specificity

5.1 Delivery Vehicles

Effective genome editing requires efficient delivery of the Cas effector and guide RNA (or their encoding nucleic acids) to the target cell type in vivo or ex vivo. Commonly used strategies include viral vectors — particularly adeno-associated virus (AAV), whose small packaging capacity (~4.7 kb) is a significant constraint for larger cargoes such as prime editors, and lentivirus, which integrates into the host genome and is widely used for stable ex vivo modification in functional genomics and cell-therapy manufacturing. Non-viral approaches, including lipid nanoparticles (LNPs) delivering Cas9 mRNA and sgRNA, and direct delivery of pre-assembled ribonucleoprotein (RNP) complexes, offer transient exposure that reduces the duration of nuclease activity and, correspondingly, the cumulative probability of off-target editing. The clinical validation of LNP-mediated, hepatocyte-targeted in vivo editing by NTLA-2001 (Gillmore et al., 2021, discussed in Section 4.1) demonstrated that systemically administered, non-viral CRISPR delivery can achieve therapeutically meaningful, organ-specific gene knockdown in humans, opening a delivery paradigm distinct from ex vivo cell-therapy manufacturing.

5.2 Off-Target Detection and High-Fidelity Engineering

Because Cas9 can tolerate a limited number of mismatches between the guide RNA and genomic DNA, off-target cleavage at unintended, partially complementary loci is a central safety consideration, particularly for therapeutic applications. Genome-wide, unbiased off-target profiling methods have been developed to empirically map the off-target landscape of a given guide RNA rather than relying solely on computational sequence-similarity prediction. One widely adopted approach, GUIDE-seq, integrates a short double-stranded oligonucleotide tag at Cas9-induced break sites throughout the genome, which are then mapped by high-throughput sequencing, providing an unbiased, cell-based readout of off-target cleavage frequency and location (Tsai et al., 2015). Comparable profiling of the Cas12a (Cpf1) effector family found substantially fewer detectable off-target sites than typically observed for wild-type Cas9 under similar conditions (Kleinstiver et al., 2016), informing effector choice for specificity-sensitive applications. These empirical findings have, in turn, informed the rational engineering of high-fidelity Cas9 variants carrying mutations that weaken non-specific DNA contacts, substantially improving specificity while largely preserving on-target activity.

5.3 Practical Implications for Research Design

For researchers designing CRISPR experiments, guide RNA selection tools that integrate on-target efficiency prediction with off-target risk scoring, combined with orthogonal validation (e.g., Sanger or amplicon deep sequencing at predicted off-target sites), remain essential good practice, particularly as editing outcomes are increasingly used to inform clinical and regulatory decisions.

6. CRISPR-Based Molecular Diagnostics

6.1 The Collateral-Cleavage Principle

A parallel line of research exploited an unexpected biochemical property of certain Class 2 Cas effectors: upon recognising their intended target, some Cas proteins enter a state of indiscriminate ('collateral' or 'trans') nuclease activity against nearby single-stranded nucleic acids, distinct from the sequence-specific ('cis') cleavage of the bound target itself. This property, first characterised in detail for the RNA-targeting effector Cas13a and subsequently for the DNA-targeting effector Cas12a, converts a highly specific recognition event into an amplifiable, easily read-out signal — the biochemical basis of an entire generation of CRISPR diagnostics. Figure 5 illustrates this mechanism schematically.



Figure 5. Collateral (trans) cleavage biochemistry underlying CRISPR diagnostics. Prior to target recognition, the Cas effector-crRNA complex is catalytically quiescent and quenched fluorescent reporters remain intact. Upon binding cognate target DNA or RNA, the effector is allosterically activated and indiscriminately cleaves nearby single-stranded reporter molecules, releasing a fluorescent, colourimetric, or lateral-flow signal.

6.2 SHERLOCK

Specific High-Sensitivity Enzymatic Reporter unLOCKing (SHERLOCK) couples isothermal recombinase polymerase amplification (RPA) with Cas13a-mediated collateral cleavage of a quenched fluorescent RNA reporter, enabling attomolar-sensitivity detection of specific RNA or DNA sequences, including discrimination of Zika and Dengue virus strains and human genotyping from cell-free DNA (Gootenberg et al., 2017). A second-generation platform, SHERLOCKv2, introduced four-channel multiplexing using orthogonal CRISPR enzymes (Cas13, Cas12a, and the auxiliary nuclease Csm6), quantitative readout down to roughly two attomolar input, and a lateral-flow paper-strip format compatible with point-of-care use (Gootenberg et al., 2018). Subsequent protocol papers standardised SHERLOCK for field and clinical deployment, including lyophilisation of reaction components for cold-chain-independent storage (Kellner et al., 2019).

6.3 DETECTR

A parallel diagnostic platform, DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter), exploits the discovery that Cas12a, upon binding double-stranded target DNA, unleashes indiscriminate single-stranded DNase ('trans-cleavage') activity (Chen et al., 2018). Combined with isothermal amplification (typically RPA or LAMP), this collateral ssDNA cleavage is harnessed to release a fluorescent or lateral-flow reporter, providing rapid, visually interpretable nucleic acid detection without a thermocycler.

6.4 Clinical Validation During the COVID-19 Pandemic

The urgency of the COVID-19 pandemic provided an unusually rapid, real-world validation of CRISPR diagnostics. A Cas12-based lateral-flow assay for SARS-CoV-2, built on the DETECTR platform, achieved approximately ninety-five percent positive predictive agreement and one hundred percent negative predictive agreement with the U.S. CDC's reference RT-PCR assay, with a total turnaround time under one hour (Broughton et al., 2020). Related SHERLOCK-based one-pot assays and numerous Cas12b- and Cas13-based variants were similarly validated against clinical respiratory samples, collectively demonstrating that CRISPR diagnostics could match the analytical sensitivity of PCR while removing the requirement for specialised thermocycling equipment — an important consideration for decentralised and resource-limited testing settings.

6.5 General Diagnostic Workflow

Despite differences in the specific Cas effector employed, CRISPR diagnostic platforms share a common four-stage biochemical workflow, illustrated in Figure 6: sample collection and nucleic acid extraction; isothermal pre-amplification (commonly RPA or LAMP); Cas-crRNA-mediated target recognition; and collateral reporter cleavage, culminating in a fluorescent, colourimetric, or lateral-flow readout.



Figure 6. General workflow of CRISPR-based nucleic acid diagnostics, applicable to both SHERLOCK (Cas13a) and DETECTR (Cas12a) platforms, from sample collection through isothermal amplification, Cas-mediated target recognition, and reporter-based readout.

6.6 Comparative Performance

Table 2 compares CRISPR-based diagnostics against conventional qRT-PCR and non-CRISPR isothermal amplification (LAMP) across key performance parameters relevant to research and point-of-care deployment.

Table 2. Comparative performance of nucleic acid detection platforms.

Parameter	qRT-PCR	SHERLOCK	DETECTR	LAMP (non-CRISPR)
Effector / chemistry	Taq polymerase, fluorescent probe	Cas13a + RPA	Cas12a + RPA/LAMP	Strand-displacing polymerase
Thermocycler required	Yes	No (isothermal)	No (isothermal)	No (isothermal)
Approx. sensitivity	Single copies (gold standard)	~2 attomolar	Comparable to qPCR	Moderate; prone to false positives
Turnaround time	1.5-3 hours	~1 hour	~30-45 minutes	~30-60 minutes
Readout	Fluorescence (instrument)	Fluorescence / lateral flow	Lateral flow / fluorescence	Colourimetric / turbidity
Key reference	Standard clinical method	Gootenberg et al., 2017, 2018	Chen et al., 2018; Broughton et al., 2020	Notomi et al. (cited in Broughton et al., 2020)

6.7 Biochemical and Engineering Considerations

Robust CRISPR diagnostics depend on the interplay of several biochemical modules: an isothermal pre-amplification step to raise target copy number into the detectable range; a Cas effector-crRNA complex engineered or selected for high collateral turnover and low background activity; and a reporter chemistry matched to the intended point-of-care or laboratory context. Engineering efforts have since focused on improving crRNA design for single-nucleotide discrimination (enabling genotyping and variant calling), on lyophilisation for cold-chain-independent field deployment, and on multiplexed, single-reaction detection of multiple pathogens or genotypes simultaneously using orthogonal Cas effectors with distinct collateral substrate preferences (Gootenberg et al., 2018).

6.8 Electronic and Amplification-Free Readout

A further diagnostic innovation dispenses with optical reporters altogether. CRISPR-Chip couples catalytically inactive Cas9 (dCas9), pre-complexed with a target-specific sgRNA, to a graphene-based field-effect transistor: target binding by the immobilised dCas9-sgRNA complex produces a measurable change in the transistor's electrical conductance, yielding a label-free, amplification-free digital readout of a specific genomic sequence within approximately fifteen minutes, validated against clinical DNA samples carrying Duchenne muscular dystrophy-associated deletions (Hajian et al., 2019). Because this approach requires no fluorescent reporter, isothermal amplification step, or optical instrumentation, it illustrates a further trajectory for CRISPR diagnostics toward fully portable, handheld electronic biosensing, complementary to the fluorescence- and lateral-flow-based platforms described above.

7. Convergence of Editing and Diagnostic Biochemistry

Editing and diagnostic applications of CRISPR-Cas share a common biochemical foundation — programmable, PAM- or protospacer-dependent RNA-guided target recognition — but diverge sharply in how that recognition event is converted into a biological outcome: precise DNA modification in the case of editing, versus amplifiable collateral cleavage in the case of diagnostics. This convergence has practical implications for genetic and biochemical research: the same guide-RNA design principles, off-target prediction tools, and Cas-protein engineering pipelines developed for therapeutic editing directly inform the specificity and robustness of diagnostic assays, and vice versa. Emerging 'detect-and-edit' or theranostic concepts, in which a single CRISPR platform first genotypes a sample and then informs a downstream editing decision, illustrate the translational potential of this convergence, particularly for companion-diagnostic applications ahead of genotype-specific therapeutic editing.

8. Agricultural, Environmental, and Field-Deployable Applications

Beyond human therapeutics, CRISPR diagnostics have found substantial application in plant pathogen surveillance, livestock disease monitoring, and environmental biosurveillance, where the elimination of cold-chain and thermocycler requirements is particularly valuable in field and low-resource settings. Rapid, lateral-flow CRISPR assays for plant viruses and bacterial pathogens allow on-site genotyping of crop disease outbreaks without requiring samples to be transported to a centralised laboratory, shortening the interval between detection and intervention. Similarly, CRISPR-edited crop varieties with improved abiotic stress tolerance and disease resistance are of direct relevance to integrated soil-health and precision-agriculture research programmes, where genomic tools increasingly complement remote-sensing and geospatial monitoring approaches.

9. Ethical, Regulatory, and Governance Considerations

Several challenges continue to shape the trajectory of CRISPR-based genetic and biochemical research. Off-target editing, though substantially reduced by high-fidelity Cas9 variants, base editors, and prime editors, remains a central safety consideration for therapeutic applications, particularly where edited cells are reintroduced into patients. Delivery — particularly of large editing constructs such as prime editors — to specific tissues in vivo remains a bottleneck, driving continued interest in compact Cas orthologues and improved non-viral delivery vehicles.

Germline (heritable) genome editing raises distinct and more far-reaching ethical questions than somatic editing, since heritable edits would be transmitted to future generations without their consent and could have unpredictable long-term population-level effects. These concerns were brought into sharp public focus in November 2018, when a researcher in China announced the birth of twin girls whose embryos had reportedly been edited using CRISPR-Cas9 to disrupt the CCR5 gene, a claim that provoked immediate and near-universal condemnation from the international scientific community on grounds spanning inadequate evidence of medical necessity, insufficient safety data, and a fundamental breach of research ethics and consent norms. This episode catalysed renewed international efforts toward formal governance frameworks for heritable human genome editing, and the broad scientific consensus that has since prevailed is that clinical application of heritable human genome editing remains premature pending far more extensive safety data, robust international governance, and broader societal consensus. On the diagnostic side, standardisation of amplification chemistries, clear regulatory pathways for point-of-care CRISPR assays (including emergency-use authorisation frameworks demonstrated during the COVID-19 pandemic), and integration with digital or smartphone-based readout systems remain active areas of methodological and policy development. Equitable access to both CRISPR therapeutics and diagnostics — particularly given the substantial manufacturing cost of ex vivo cell therapies such as exa-cel — represents an ongoing translational and policy challenge distinct from, but informed by, the underlying biochemical advances reviewed in this chapter.

10. CONCLUSION AND FUTURE DIRECTIONS

CRISPR-Cas biology has evolved from a bacterial immune curiosity into a dual-purpose biochemical platform underpinning both precision genome editing and rapid molecular diagnostics. The mechanistic understanding of RNA-guided target recognition, double-strand-break repair, base-conversion chemistry, prime-editing template writing, and collateral nuclease activity has enabled a coherent toolkit spanning basic genetic research, functional genomics, agricultural biotechnology, clinical therapeutics such as exa-cel, and field-deployable diagnostics validated at pandemic scale.

Future research directions are likely to include further miniaturisation of Cas effectors to ease delivery constraints, continued improvement of prime-editing efficiency and product purity, integration of CRISPR diagnostics with digital and artificial-intelligence-assisted readout for decentralised testing networks, and expanded application of theranostic 'detect-and-edit' platforms. Continued refinement of specificity, delivery, and assay design, alongside deliberate, internationally coordinated ethical governance, will determine how fully this convergence of editing and diagnostic biochemistry is realised across genetics and biomedical research over the coming decade.

REFERENCES

1. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-821.
2. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819-823.
3. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823-826.
4. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533, 420-424.
5. Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature, 551, 464-471.
6. Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576, 149-157.
7. Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020). Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nature Biotechnology, 38, 824-844.
8. Gootenberg, J. S., Abudayyeh, O. O., Lee, J. W., Essletzbichler, P., Dy, A. J., Joung, J., Verdine, V., Donghia, N., Daringer, N. M., Freije, C. A., Myhrvold, C., Bhattacharyya, R. P., Livny, J., Regev, A., Koonin, E. V., Hung, D. T., Sabeti, P. C., Collins, J. J., & Zhang, F. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356(6336), 438-442.
9. Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., Joung, J., Collins, J. J., & Zhang, F. (2018). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science, 360(6387), 439-444.
10. Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O., & Zhang, F. (2019). SHERLOCK: nucleic acid detection with CRISPR nucleases. Nature Protocols, 14, 2986-3012.
11. Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360(6387), 436-439.
12. Broughton, J. P., Deng, X., Yu, G., Fasching, C. L., Servellita, V., Singh, J., Miao, X., Streithorst, J. A., Granados, A., Sotomayor-Gonzalez, A., Zorn, K., Gopez, A., Hsu, E., Gu, W., Miller, S., Pan, C.-Y., Guevara, H., Wadford, D. A., Chen, J. S., & Chiu, C. Y. (2020). CRISPR-Cas12-based detection of SARS-CoV-2. Nature Biotechnology, 38, 870-874.
13. U.S. Food and Drug Administration. (2023). FDA approves first gene therapies to treat patients with sickle cell disease [Press announcement]. U.S. FDA.
14. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
15. Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., & Zhang, F. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 343(6166), 84-87.
16. Sapranauskas, R., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., & Siksnys, V. (2011). The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Research, 39, 9275-9282.
17. Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology, 169(12), 5429-5433.
18. Jansen, R., van Embden, J. D. A., Gaastra, W., & Schouls, L. M. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology, 43(6), 1565-1575.
19. Mojica, F. J. M., Díez-Villaseñor, C., García-Martínez, J., & Soria, E. (2005). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. Journal of Molecular Evolution, 60, 174-182.
20. Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., Koonin, E. V., & Zhang, F. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 163(3), 759-771.
21. Kleinstiver, B. P., Tsai, S. Q., Prew, M. S., Nguyen, N. T., Welch, M. M., Lopez, J. M., McCaw, Z. R., Aryee, M. J., & Joung, J. K. (2016). Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nature Biotechnology, 34, 869-874.
22. Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K. (2015). GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature Biotechnology, 33, 187-197.
23. Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O'Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., ... Lebwohl, D. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385, 493-502.

24. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., de Montalembert, M., Rondelli, D., ... Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384, 252-260.
25. Hajian, R., Balderston, S., Tran, T., deBoer, T., Etienne, J., Sandhu, M., Wauford, N. A., Chung, J.-Y., Nokes, J., Athaiya, M., Paredes, J., Peytavi, R., Goldsmith, B., Murthy, N., Conboy, I. M., & Aran, K. (2019). Detection of unamplified target genes via CRISPR-Cas9 immobilized on a graphene field-effect transistor. Nature Biomedical Engineering, 3, 427-437.
26. Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152(5), 1173-1183.
27. Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., Lim, W. A., Weissman, J. S., & Qi, L. S. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 154(2), 442-451.
28. Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science, 315(5819), 1709-1712.
29. Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 471, 602-607.
30. Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell, 156(5), 935-949.
31. Bondy-Denomy, J., Pawluk, A., Maxwell, K. L., & Davidson, A. R. (2013). Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature, 493, 429-432.
32. Zuo, E., Sun, Y., Wei, W., Yuan, T., Ying, W., Sun, H., Yuan, L., Steinmetz, L. M., Li, Y., & Yang, H. (2019). Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science, 364(6437), 289-292.
33. Jin, S., Zong, Y., Gao, Q., Zhu, Z., Wang, Y., Qin, P., Liang, C., Wang, D., Qiu, J.-L., Zhang, F., & Gao, C. (2019). Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science, 364(6437), 292-295.